SIK2 and neoplasm: Critically, among LARC patients who received nCRT, the proportion of patients with high SIK2 expression in pre‐treatment biopsies in the incomplete tumor regression group was significantly higher than that in the complete tumor regression group (GSE133057; Figure 1H).